Gilead Sciences Stock Price, News & Analysis (NASDAQ:GILD)

$79.02 -0.04 (-0.05 %)
(As of 01/16/2018 02:48 AM ET)
Previous Close$79.06
Today's Range$78.65 - $79.40
52-Week Range$63.76 - $86.27
Volume6.37 million shs
Average Volume8.07 million shs
Market Capitalization$103.19 billion
P/E Ratio8.99
Dividend Yield2.63%

About Gilead Sciences (NASDAQ:GILD)

Gilead Sciences logoGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs


Debt-to-Equity Ratio1.10%
Current Ratio3.68%
Quick Ratio3.56%


Trailing P/E Ratio8.98976109215017
Forward P/E Ratio9.26
P/E Growth-1.68

Sales & Book Value

Annual Sales$30.39 billion
Price / Sales3.40
Cash Flow$12.60 per share
Price / Cash6.27
Book Value$14.70 per share
Price / Book5.38


Trailing EPS$8.79
Net Income$13.50 billion
Net Margins42.22%
Return on Equity57.15%
Return on Assets21.14%


Outstanding Shares1,306,270,000

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Thursday, October 26th. Stockholders of record on Friday, December 15th will be paid a dividend of $0.52 per share on Thursday, December 28th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.63%. The ex-dividend date is Thursday, December 14th. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings results on Thursday, October, 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the consensus estimate of $2.13 by $0.14. The biopharmaceutical company earned $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business's revenue for the quarter was down 13.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.75 EPS. View Gilead Sciences' Earnings History.

When will Gilead Sciences make its next earnings announcement?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, February, 6th 2018. View Earnings Estimates for Gilead Sciences.

Where is Gilead Sciences' stock going? Where will Gilead Sciences' stock price be in 2018?

27 Wall Street analysts have issued 12 month price objectives for Gilead Sciences' shares. Their forecasts range from $68.00 to $96.00. On average, they expect Gilead Sciences' stock price to reach $85.34 in the next year. View Analyst Ratings for Gilead Sciences.

What are Wall Street analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:

  • 1. According to Zacks Investment Research, "Gilead’s HCV franchise is under tremendous pressure due to lower patient starts and increasing competition. Higher discounts and payer mix continue to hurt sales. Sales are expected to decline further. Moreover, Gilead has lost exclusivity for Viread and Truvada. Meanwhile, the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens in the United States and EU. The TAF-based regimens now represent 56% of total Gilead HIV prescription volume following the launch of Genvoya and the launches of Odefsey and Descovy in 2016. Shares of the company have outperformed the industry in the last six months. However, Gilead also faces competition from generic HIV products. The acquisition of Kite and the subsequent approval of Yescarta bodes well for Gilead given the potential in the CAR T therapy. " (12/27/2017)
  • 2. Maxim Group analysts commented, "We returned from Beijing, China and listened as Tim Moore, EVP of Technical Operations and the CEO of Fosun Kite Biotechnology co. (Richard Wang) presented manufacturing plans for the launch of Yescarta, and the opportunity in China (see the slides in the pages that follow). Suffice to say, we were impressed and left clear with the notion that Gilead (and Kite) can overcome manufacturing challenges to commercialize in the U.S. and globally, especially China, this new innovative therapy. As a result, we are upgrading Gilead to Buy, from Hold and establishing a $94 price target." (11/30/2017)
  • 3. Jefferies Group LLC analysts commented, "U.S. sales of Harvoni are tracking in line for 1Q and Epclusa ahead of cons., which should help GILD hit numbers for now and perhaps improve sentiment. We are cautious about overinterpreting recent Rx trends given VA/pricing dynamics are not captured and many headwinds could increase over '17, and remain below cons. for out-yrs. Still, we like GILD on LT HIV sustainability and BD optionality, and believe any deal & acceptable HCV 1Q #s could improve sentiment." (3/15/2017)

Are investors shorting Gilead Sciences?

Gilead Sciences saw a drop in short interest in the month of December. As of December 29th, there was short interest totalling 17,982,588 shares, a drop of 23.5% from the December 15th total of 23,511,423 shares. Based on an average daily volume of 6,470,028 shares, the short-interest ratio is currently 2.8 days. Approximately 1.4% of the shares of the company are short sold.

Who are some of Gilead Sciences' key competitors?

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:

  • John C. Martin Ph.D., Chairman of the Board (Age 65)
  • John F. Milligan Ph.D., President, Chief Executive Officer, Director (Age 55)
  • Robin L. Washington, Chief Financial Officer, Executive Vice President (Age 54)
  • Kevin B. Young, Chief Operating Officer (Age 59)
  • Norbert W. Bischofberger Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer (Age 61)
  • Gregg H. Alton, Executive Vice President - Corporate and Medical Affairs (Age 51)
  • James R. Meyers, Executive Vice President - Worldwide Commercial Operations (Age 52)
  • John F. Cogan Jr. Ph.D., Lead Independent Director (Age 69)
  • Kelly A. Kramer, Independent Director (Age 49)
  • Kevin E. Lofton, Independent Director (Age 62)

Who owns Gilead Sciences stock?

Gilead Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Nisa Investment Advisors LLC (0.04%), Hexavest Inc. (0.04%), Sit Investment Associates Inc. (0.02%), Foundation Resource Management Inc. (0.02%), Exxonmobil Investment Management Inc. TX (0.02%) and Hikari Power Ltd (0.01%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Who sold Gilead Sciences stock? Who is selling Gilead Sciences stock?

Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including Exxonmobil Investment Management Inc. TX, Private Asset Management Inc., Addenda Capital Inc., Private Capital Advisors Inc., Pointe Capital Management LLC, Berson & Corrado Investment Advisors LLC, West Oak Capital LLC and Sheets Smith Wealth Management. Company insiders that have sold Gilead Sciences company stock in the last year include Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

Who bought Gilead Sciences stock? Who is buying Gilead Sciences stock?

Gilead Sciences' stock was acquired by a variety of institutional investors in the last quarter, including Sit Investment Associates Inc., QUANTRES ASSET MANAGEMENT Ltd, Bristol Advisors LLC, Aurora Investment Counsel, American National Bank, Franklin Street Advisors Inc. NC, Hikari Power Ltd and Nisa Investment Advisors LLC. View Insider Buying and Selling for Gilead Sciences.

How do I buy Gilead Sciences stock?

Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of Gilead Sciences stock can currently be purchased for approximately $79.02.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $103.19 billion and generates $30.39 billion in revenue each year. The biopharmaceutical company earns $13.50 billion in net income (profit) each year or $8.79 on an earnings per share basis. Gilead Sciences employs 9,000 workers across the globe.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DR, FOSTER CITY, CA 94404, United States. The biopharmaceutical company can be reached via phone at +1-650-5743000 or via email at [email protected]

MarketBeat Community Rating for Gilead Sciences (GILD)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  1,656 (Vote Outperform)
Underperform Votes:  610 (Vote Underperform)
Total Votes:  2,266
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Gilead Sciences (NASDAQ:GILD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.562.632.632.62
Ratings Breakdown: 0 Sell Rating(s)
12 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $85.34$85.42$86.23$80.49
Price Target Upside: 14.30% upside15.10% upside3.84% upside14.04% upside

Gilead Sciences (NASDAQ:GILD) Consensus Price Target History

Price Target History for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/3/2018Credit Suisse GroupSet Price TargetHold$80.00LowView Rating Details
1/3/2018BMO Capital MarketsReiterated RatingHoldLowView Rating Details
12/21/2017OppenheimerReiterated RatingHoldMediumView Rating Details
12/11/2017Maxim GroupSet Price TargetBuy$94.00MediumView Rating Details
11/13/2017ArgusDowngradeBuy -> Hold$73.25 -> $73.77N/AView Rating Details
11/8/2017MizuhoBoost Price TargetBuy$77.00 -> $83.00N/AView Rating Details
10/25/2017JPMorgan Chase & Co.Set Price TargetBuy$85.00N/AView Rating Details
10/19/2017Leerink SwannBoost Price TargetMarket Perform$84.00 -> $85.00N/AView Rating Details
10/19/2017William BlairReiterated RatingBuyN/AView Rating Details
10/19/2017Berenberg BankSet Price TargetBuy$96.00N/AView Rating Details
10/11/2017BarclaysReiterated RatingOverweight -> Overweight$90.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingEqual Weight$77.00 -> $83.00N/AView Rating Details
10/5/2017CIBCInitiated CoverageMarket Perform -> Market PerformN/AView Rating Details
10/5/2017Jefferies GroupInitiated CoverageHold -> PositiveN/AView Rating Details
10/4/2017Bank of AmericaLower Price TargetNeutral$87.00 -> $86.00LowView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$94.00LowView Rating Details
9/6/2017Wells Fargo & CoBoost Price TargetMarket Perform$73.00 -> $81.00LowView Rating Details
8/31/2017CowenReiterated RatingOutperform$90.00MediumView Rating Details
8/31/2017Deutsche BankReiterated RatingBuy$81.00MediumView Rating Details
8/28/2017Needham & Company LLCReiterated RatingHoldLowView Rating Details
8/29/2017Robert W. BairdReiterated RatingOutperform$87.00LowView Rating Details
7/26/2017Redburn PartnersInitiated CoverageBuyMediumView Rating Details
5/3/2017GabelliReiterated RatingBuy$85.00MediumView Rating Details
5/3/2017Stifel NicolausReiterated RatingBuy$87.00MediumView Rating Details
4/21/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
3/13/2017Goldman Sachs GroupReiterated RatingNeutral$70.00 -> $68.00LowView Rating Details
2/8/2017CitigroupDowngradeBuy -> Neutral$87.00 -> $76.00N/AView Rating Details
10/15/2016Evercore ISISet Price TargetBuy$90.00N/AView Rating Details
7/27/2016S&P Equity ResearchReiterated RatingStrong-BuyN/AView Rating Details
2/3/2016Standpoint ResearchInitiated CoverageBuy$110.00N/AView Rating Details
(Data available from 1/16/2016 forward)


Gilead Sciences (NASDAQ:GILD) Earnings History and Estimates Chart

Earnings by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ GILD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2018$1.71N/AView Earnings Details
10/26/2017Q3 2017$2.13$2.27$6.40 billion$6.51 billionViewN/AView Earnings Details
7/26/2017Q2 2017$2.11$2.56$6.35 billion$7.14 billionViewN/AView Earnings Details
5/2/2017Q1 2017$2.18$2.20$6.66 billion$6.51 billionViewListenView Earnings Details
2/7/2017Q416$2.61$2.70$7.16 billion$7.30 billionViewListenView Earnings Details
11/1/2016Q316$2.87$2.75$7.47 billion$7.40 billionViewListenView Earnings Details
7/25/2016Q216$3.02$3.08$7.80 billion$7.78 billionViewListenView Earnings Details
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details
7/28/2015Q215$2.83$3.15$7.60 billion$8.22 billionViewListenView Earnings Details
4/30/2015Q115$2.78$2.94$6.81 billion$7.59 billionViewListenView Earnings Details
2/3/2015Q414$2.27$2.43$6.68 million$7.31 billionViewListenView Earnings Details
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details
7/23/2014Q214$1.61$2.36$5.68 billion$6.53 billionViewListenView Earnings Details
4/22/2014Q114$0.75$1.48$3.80 billion$5.00 billionViewListenView Earnings Details
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details
10/29/2013Q313$0.48$0.52$2.72 billion$2.78 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details
5/2/2013Q1 2013$0.50$0.48$2.57 billion$2.53 billionViewListenView Earnings Details
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.59 billionViewListenView Earnings Details
10/23/2012$0.94$1.00ViewN/AView Earnings Details
7/26/2012$0.95$0.99ViewN/AView Earnings Details
4/26/2012$0.94$0.91ViewN/AView Earnings Details
2/2/2012$1.04$0.97ViewN/AView Earnings Details
10/27/2011$1.01$1.02ViewN/AView Earnings Details
7/26/2011Q2 2011$0.48$0.47ViewN/AView Earnings Details
4/20/2011$0.97$0.87ViewN/AView Earnings Details
1/25/2011$0.95$0.95ViewN/AView Earnings Details
10/19/2010Q3 2010$0.42$0.43ViewN/AView Earnings Details
7/20/2010Q2 2010$0.41$0.40ViewN/AView Earnings Details
4/20/2010Q1 2010$0.46$0.47ViewN/AView Earnings Details
1/26/2010Q4 2009$0.41$0.45ViewN/AView Earnings Details
10/20/2009Q3 2009$0.35$0.37ViewN/AView Earnings Details
7/21/2009Q2 2009$0.31$0.33ViewN/AView Earnings Details
4/21/2009Q1 2009$0.30$0.32ViewN/AView Earnings Details
1/27/2009Q4 2008$0.28$0.30ViewN/AView Earnings Details
10/16/2008Q3 2008$0.25$0.26ViewN/AView Earnings Details
7/17/2008Q2 2008$0.25$0.23ViewN/AView Earnings Details
4/16/2008Q1 2008$0.24$0.26ViewN/AView Earnings Details
1/23/2008Q4 2007$0.21$0.21ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Gilead Sciences (NASDAQ:GILD) Earnings Estimates

2018 EPS Consensus Estimate: $6.58
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$1.58$1.78$1.68
Q2 20182$1.54$1.76$1.65
Q3 20182$1.49$1.74$1.62
Q4 20182$1.52$1.74$1.63
(Earnings estimates data provided by Zacks Investment Research)


Gilead Sciences (NASDAQ:GILD) Dividend Information

Most Recent Dividend:12/28/2017
Annual Dividend:$2.08
Dividend Yield:2.63%
Payout Ratio:23.66% (Trailing 12 Months of Earnings)
24.38% (Based on This Year's Estimates)
30.95% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Gilead Sciences (NASDAQ GILD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.30%
Institutional Ownership Percentage: 75.95%
Insider Trades by Quarter for Gilead Sciences (NASDAQ:GILD)
Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ GILD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2018Gregg H AltonEVPSell15,000$73.87$1,108,050.0064,613View SEC Filing  
1/2/2018John C MartinInsiderSell50,000$73.62$3,681,000.003,046,766View SEC Filing  
12/1/2017Gregg H AltonEVPSell15,000$74.64$1,119,600.0070,988View SEC Filing  
12/1/2017John C MartinInsiderSell73,333$74.98$5,498,508.343,070,099View SEC Filing  
11/13/2017John F MilliganInsiderSell220,000$72.88$16,033,600.00View SEC Filing  
11/1/2017Gregg H AltonEVPSell15,000$74.82$1,122,300.0077,363View SEC Filing  
11/1/2017John C MartinInsiderSell73,333$75.13$5,509,508.293,070,099View SEC Filing  
10/2/2017Gregg H AltonEVPSell25,000$82.65$2,066,250.00View SEC Filing  
10/2/2017John C MartinInsiderSell73,333$82.56$6,054,372.48View SEC Filing  
9/7/2017Robin L WashingtonCFOSell51,820$85.00$4,404,700.0043,352View SEC Filing  
9/1/2017Gregg H AltonEVPSell25,000$83.05$2,076,250.00101,488View SEC Filing  
9/1/2017John C MartinInsiderSell73,333$83.11$6,094,705.632,996,766View SEC Filing  
8/31/2017James R MeyersEVPSell60,000$83.19$4,991,400.0062,715View SEC Filing  
8/30/2017Gregg H AltonEVPSell50,000$79.00$3,950,000.00113,237View SEC Filing  
8/1/2017Gregg H AltonEVPSell15,000$75.88$1,138,200.00106,113View SEC Filing  
8/1/2017John C MartinInsiderSell73,333$75.86$5,563,041.383,199,969View SEC Filing  
7/21/2017Gregg H AltonEVPSell40,000$74.00$2,960,000.00137,488View SEC Filing  
7/3/2017Gregg H AltonEVPSell5,000$71.06$355,300.00102,988View SEC Filing  
7/3/2017John C MartinInsiderSell73,333$71.00$5,206,643.003,199,969View SEC Filing  
5/9/2017John Francis CoganDirectorSell9,943$67.25$668,666.7547,562View SEC Filing  
4/3/2017John C MartinInsiderSell73,333$67.18$4,926,510.943,199,969View SEC Filing  
3/30/2017Gregg H AltonEVPSell5,000$67.48$337,400.00117,988View SEC Filing  
1/3/2017John C MartinInsiderSell73,337$73.59$5,396,869.833,204,433View SEC Filing  
11/18/2016John W MadiganDirectorSell105,000$74.86$7,860,300.00121,761View SEC Filing  
10/3/2016John C MartinInsiderSell100,000$77.63$7,763,000.003,231,096View SEC Filing  
9/22/2016Gregg H AltonEVPSell5,000$81.84$409,200.00132,964View SEC Filing  
9/6/2016John F MilliganInsiderSell70,000$77.74$5,441,800.001,128,963View SEC Filing  
9/1/2016John C MartinInsiderSell100,000$77.48$7,748,000.003,287,810View SEC Filing  
8/24/2016Kevin E LoftonDirectorSell3,500$81.97$286,895.00View SEC Filing  
8/1/2016John C MartinInsiderSell100,000$80.50$8,050,000.004,119,727View SEC Filing  
8/1/2016Paul Rutherford CarterEVPSell2,000$79.81$159,620.0064,122View SEC Filing  
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.001,170,963View SEC Filing  
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.004,119,727View SEC Filing  
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.0063,122View SEC Filing  
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.001,170,963View SEC Filing  
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.0063,122View SEC Filing  
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.004,119,727View SEC Filing  
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.001,170,963View SEC Filing  
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.0062,939View SEC Filing  
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00177,964View SEC Filing  
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.001,170,963View SEC Filing  
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.004,119,727View SEC Filing  
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.0063,122View SEC Filing  
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00147,090View SEC Filing  
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50110,523View SEC Filing  
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.003,948,066View SEC Filing  
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.0048,783View SEC Filing  
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.003,948,066View SEC Filing  
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.0048,783View SEC Filing  
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00127,936View SEC Filing  
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.001,029,108View SEC Filing  
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.0044,309View SEC Filing  
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00131,422View SEC Filing  
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.003,948,066View SEC Filing  
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.0044,309View SEC Filing  
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00133,422View SEC Filing  
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.0044,309View SEC Filing  
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00165,168View SEC Filing  
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.001,029,108View SEC Filing  
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00133,422View SEC Filing  
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.003,948,066View SEC Filing  
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.0048,783View SEC Filing  
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00135,422View SEC Filing  
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.0044,309View SEC Filing  
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.001,029,108View SEC Filing  
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.003,948,066View SEC Filing  
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00101,769View SEC Filing  
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.213,948,066View SEC Filing  
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00119,302View SEC Filing  
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.0049,832View SEC Filing  
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00130,694View SEC Filing  
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.504,429,387View SEC Filing  
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.0012,778View SEC Filing  
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.0049,832View SEC Filing  
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00119,302View SEC Filing  
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.0039,542View SEC Filing  
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.8428,562View SEC Filing  
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00132,694View SEC Filing  
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.504,429,387View SEC Filing  
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.0039,542View SEC Filing  
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00119,302View SEC Filing  
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.9628,562View SEC Filing  
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.0084,484View SEC Filing  
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.504,257,235View SEC Filing  
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00216,418View SEC Filing  
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.0032,938View SEC Filing  
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.002,159,643View SEC Filing  
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00161,840View SEC Filing  
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.002,159,643View SEC Filing  
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.0046,938View SEC Filing  
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.744,057,121View SEC Filing  
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.002,159,643View SEC Filing  
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Gilead Sciences (NASDAQ GILD) News Headlines

See what the IHS Markit Score report has to say about Gilead Sciences Inc.See what the IHS Markit Score report has to say about Gilead Sciences Inc. - January 13 at 10:00 AM
Gilead Sciences, Inc. (GILD) Short Interest Down 23.5% in DecemberGilead Sciences, Inc. (GILD) Short Interest Down 23.5% in December - January 13 at 3:15 AM
2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better - January 12 at 10:03 AM
New Year, New Gilead? Its No Longer Just About Hepatitis CNew Year, New Gilead? It's No Longer Just About Hepatitis C - January 11 at 4:54 PM
Tax cuts are barely priced into earnings expectations: NYSE traderTax cuts are barely priced into earnings expectations: NYSE trader - January 10 at 4:46 PM
Gileads Breakout May Spark 18% GainGilead's Breakout May Spark 18% Gain - January 10 at 10:13 AM
5 Ways Gilead Sciences Plans to Return to Growth5 Ways Gilead Sciences Plans to Return to Growth - January 9 at 4:50 PM
Gilead CEO: We still intend to invest in M&A and our pipe...Gilead CEO: We still intend to invest in M&A and our pipe... - January 9 at 4:50 PM
Noteworthy Friday Option Activity: GILD, AVXS, UAANoteworthy Friday Option Activity: GILD, AVXS, UAA - January 5 at 4:30 PM
Why 2017 Was a Year to Remember for Gilead Sciences, Inc.Why 2017 Was a Year to Remember for Gilead Sciences, Inc. - January 5 at 9:51 AM
Gregg H. Alton Sells 15,000 Shares of Gilead Sciences, Inc. (GILD) StockGregg H. Alton Sells 15,000 Shares of Gilead Sciences, Inc. (GILD) Stock - January 4 at 9:28 PM
Insider Selling: Gilead Sciences, Inc. (GILD) Insider Sells 50,000 Shares of StockInsider Selling: Gilead Sciences, Inc. (GILD) Insider Sells 50,000 Shares of Stock - January 4 at 9:28 PM
Gilead Will Be a Buy at Some Point. Some Point Isnt Now.Gilead Will Be a Buy at 'Some Point.' Some Point Isn't Now. - January 4 at 10:04 AM
Credit Suisse Group Reiterates "$80.00" Price Target for Gilead Sciences (GILD)Credit Suisse Group Reiterates "$80.00" Price Target for Gilead Sciences (GILD) - January 3 at 7:10 PM
Here's How bluebird bio, Inc. Crushed It in 2017Here's How bluebird bio, Inc. Crushed It in 2017 - January 2 at 5:42 PM
Gilead Sciences, Inc. (GILD) Receives Consensus Recommendation of "Buy" from BrokeragesGilead Sciences, Inc. (GILD) Receives Consensus Recommendation of "Buy" from Brokerages - January 1 at 11:50 AM
Gilead Sciences, Inc. (GILD) Expected to Announce Quarterly Sales of $5.74 BillionGilead Sciences, Inc. (GILD) Expected to Announce Quarterly Sales of $5.74 Billion - January 1 at 6:22 AM
Gilead Sciences, Inc. (GILD) Expected to Announce Earnings of $1.69 Per ShareGilead Sciences, Inc. (GILD) Expected to Announce Earnings of $1.69 Per Share - December 30 at 7:08 PM
Why Gilead Sciences Stock Should Be Avoided in 2018 - Motley FoolWhy Gilead Sciences Stock Should Be Avoided in 2018 - Motley Fool - December 29 at 4:42 PM
Intercept (ICPT) Stock Loses Sheen in 2017: What Lies Ahead?Intercept (ICPT) Stock Loses Sheen in 2017: What Lies Ahead? - December 29 at 9:19 AM
Why Gilead Sciences Stock Should Be Avoided in 2018Why Gilead Sciences Stock Should Be Avoided in 2018 - December 29 at 7:28 AM
Short Interest in Gilead Sciences, Inc. (GILD) Grows By 19.7%Short Interest in Gilead Sciences, Inc. (GILD) Grows By 19.7% - December 29 at 2:32 AM
Notable Wednesday Option Activity: RL, WBA, GILDNotable Wednesday Option Activity: RL, WBA, GILD - December 27 at 7:55 PM
Gilead Sciences (GILD) Downgraded by Zacks Investment Research to SellGilead Sciences (GILD) Downgraded by Zacks Investment Research to Sell - December 27 at 5:40 PM
Estimating The Intrinsic Value Of Gilead Sciences Inc (NASDAQ:GILD)Estimating The Intrinsic Value Of Gilead Sciences Inc (NASDAQ:GILD) - December 27 at 2:53 PM
Is A Company You Own Making A Dumb AcquisitionIs A Company You Own Making A Dumb Acquisition - December 23 at 12:50 AM
Gileads 2018 And Beyond - Buckle Up For A New Gilead - Seeking AlphaGilead's 2018 And Beyond - Buckle Up For A New Gilead - Seeking Alpha - December 22 at 7:49 PM
Gilead: Maybe 2018 Wont Be Its Year EitherGilead: Maybe 2018 Won't Be Its Year Either - December 22 at 10:15 AM
GEs Stock Investors Should Brace for More PainGE's Stock Investors Should Brace for More Pain - December 22 at 10:15 AM
Gilead Sciences to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8Gilead Sciences to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8 - December 21 at 4:49 PM
Gilead Sciences (GILD) Stock Rating Reaffirmed by OppenheimerGilead Sciences (GILD) Stock Rating Reaffirmed by Oppenheimer - December 21 at 1:42 PM
Gilead Sciences (GILD) Lowered to "Neutral" at Credit Suisse GroupGilead Sciences (GILD) Lowered to "Neutral" at Credit Suisse Group - December 20 at 10:56 PM
Interesting GILD Put And Call Options For August 2018Interesting GILD Put And Call Options For August 2018 - December 20 at 4:45 PM
Credit Suisse: Street Expectations Too High For Gileads Hep C TherapyCredit Suisse: Street Expectations 'Too High' For Gilead's Hep C Therapy - December 20 at 4:45 PM
Analysts’ Recommendations for Gilead Sciences in December 2017Analysts’ Recommendations for Gilead Sciences in December 2017 - December 20 at 4:45 PM
Gilead Sciences, Inc. : GILD-US: Dividend Analysis : December 15th, 2017 (record date) : By the numbers : December 19, 2017Gilead Sciences, Inc. : GILD-US: Dividend Analysis : December 15th, 2017 (record date) : By the numbers : December 19, 2017 - December 20 at 10:12 AM
A Tale of Two Biotechs: Why Biogen Beats GileadA Tale of Two Biotechs: Why Biogen Beats Gilead - December 20 at 10:12 AM
Analysts’ Expectations for Gilead SciencesAnalysts’ Expectations for Gilead Sciences - December 20 at 10:12 AM
Gilead’s Other Products in 3Q17Gilead’s Other Products in 3Q17 - December 20 at 10:12 AM
Changes in Gilead’s Revenue Trends in 3Q17Changes in Gilead’s Revenue Trends in 3Q17 - December 19 at 10:10 AM
Gilead’s HIV and Hepatitis B Portfolio in 3Q17Gilead’s HIV and Hepatitis B Portfolio in 3Q17 - December 19 at 10:10 AM
Gilead’s Hepatitis C Portfolio in 3Q17Gilead’s Hepatitis C Portfolio in 3Q17 - December 19 at 10:10 AM
Gilead Sciences - The Silver Bullet For NASH With Selonsertib And GS-9674 Combinations Treatment - Seeking AlphaGilead Sciences - The Silver Bullet For NASH With Selonsertib And GS-9674 Combinations Treatment - Seeking Alpha - December 17 at 4:48 PM
BidaskClub Upgrades Gilead Sciences (GILD) to "Hold"BidaskClub Upgrades Gilead Sciences (GILD) to "Hold" - December 17 at 6:30 AM
Novel Cancer Drug Gets Stymied by Medicare Rigid Billing SystemNovel Cancer Drug Gets Stymied by Medicare Rigid Billing System - December 16 at 10:10 AM
Even in This Rich Market, Gilead Sciences, Inc. Is Offering Investors ValueEven in This Rich Market, Gilead Sciences, Inc. Is Offering Investors Value - December 16 at 8:55 AM
Gilead & Galapagos: Lets Just Be FriendsGilead & Galapagos: Let's Just Be Friends - December 15 at 5:04 PM
Teva to launch generic version of Gileads Viread in the U.S.Teva to launch generic version of Gilead's Viread in the U.S. - December 15 at 10:36 AM
Gilead Sciences, Inc. breached its 50 day moving average in a Bearish Manner : GILD-US : December 15, 2017Gilead Sciences, Inc. breached its 50 day moving average in a Bearish Manner : GILD-US : December 15, 2017 - December 15 at 10:36 AM
$5.70 Billion in Sales Expected for Gilead Sciences, Inc. (GILD) This Quarter$5.70 Billion in Sales Expected for Gilead Sciences, Inc. (GILD) This Quarter - December 15 at 4:30 AM

SEC Filings

Gilead Sciences (NASDAQ:GILD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Gilead Sciences (NASDAQ:GILD) Income Statement, Balance Sheet and Cash Flow Statement


Gilead Sciences (NASDAQ GILD) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.